TreatSMA

A Big Thank You and Fond Farewell to Dedicated Trustee

It is with great sadness we announce the departure of Kacper from the TreatSMA team.

Kacper has been an integral part of the team and one of the original founders of TreatSMA. Kacper has been fundamental in helping TreatSMA and the community reach many goals, his role in getting access to Spinraza for people in England can not be overestimated and everybody who is currently receiving treatment owes him a debt of thanks.

As TreatSMA continues to evolve we had to take a difficult decision to part ways with Kacper in order to allow each party to grow and focus on their activities. Kacper will continue his work for SMA community within other organisations and TreatSMA will continue to develop its own sphere of work.

We wish Kacper the very best and we are certain that this departure will not prohibit further successful collaborations.

TreatSMA team.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more